Cellectar Biosciences Company Profile (NASDAQ:CLRB)

About Cellectar Biosciences

Cellectar Biosciences logo

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: CLRB
CUSIP:

Key Metrics:

Previous Close: $2.76
50 Day Moving Average: $2.61
200 Day Moving Average: $2.90
52-Week Range: $1.00 - $22.30
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -3.33
P/E Growth: 0.00
Market Cap: $14.82M
Outstanding Shares: 5,368,000
Beta: 0.37

Profitability:

Return on Equity: -60.53%
Return on Assets: -28.74%

Debt:

Current Ratio: 5.85%
Quick Ratio: 5.85%

Additional Links:

Companies Related to Cellectar Biosciences:

Consensus Ratings for Cellectar Biosciences (NASDAQ:CLRB) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Cellectar Biosciences (NASDAQ:CLRB)

Show:

No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Cellectar Biosciences (NASDAQ:CLRB)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/10/2016
8/11/2016		($0.40)	($0.49)	View	N/A
11/12/2015	Q315		($0.25)	View	Listen
8/12/2015	Q215		($0.30)	View	Listen
5/21/2015	Q115		($0.30)	View	Listen
3/26/2014		($0.04)	($0.05)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Cellectar Biosciences (NASDAQ:CLRB)

Current Year EPS Consensus Estimate: $-0.80 EPS
Next Year EPS Consensus Estimate: $-0.83 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q2 2016	1	($0.40)	($0.40)	($0.40)
Q3 2016	1	($0.20)	($0.20)	($0.20)
Q4 2016	1	($0.20)	($0.20)	($0.20)

(Data provided by Zacks Investment Research)

Dividend History for Cellectar Biosciences (NASDAQ:CLRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cellectar Biosciences (NASDAQ:CLRB)

Insider Ownership Percentage: 15.45%
Institutional Ownership Percentage: 1.97%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
4/20/2016	James V Caruso	CEO	Buy	46,948	$2.12	$99,529.76
4/20/2016	Paul L Berns	Director	Buy	117,371	$2.12	$248,826.52
12/31/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	100,000	$0.69	$69,000.00
12/29/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	82,847	$0.69	$57,164.43
12/28/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	367,966	$0.73	$268,615.18
12/22/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	7,938	$0.90	$7,144.20
12/21/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	27,621	$0.92	$25,411.32
12/17/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	71,225	$0.87	$61,965.75
12/15/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	44,965	$0.82	$36,871.30
12/4/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	50,950	$1.06	$54,007.00
11/24/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	173,802	$1.24	$215,514.48
11/24/2015	James V Caruso	CEO	Buy	1,000	$1.30	$1,300.00
11/20/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	96,806	$1.17	$113,263.02
11/20/2015	James V Caruso	CEO	Buy	1,000	$1.16	$1,160.00
11/19/2015	James V. Caruso	CEO	Buy	4,000	$1.45	$5,800.00
10/23/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	8,866	$2.00	$17,732.00
10/6/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	2,554	$2.00	$5,108.00
10/5/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	7,500	$2.04	$15,300.00
10/1/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	27,940	$2.05	$57,277.00
9/29/2015	Awm Investment Company, Inc.	Major Shareholder	Sell	24,801	$2.36	$58,530.36
8/20/2014	John Neis	Director	Buy	268,711	$3.75	$1,007,666.25
8/20/2014	Simon Pedder	CEO	Buy	13,300	$3.75	$49,875.00

(Data available from 1/1/2013 forward)

Latest Headlines for Cellectar Biosciences (NASDAQ:CLRB)

Date	Headline
	Penny Stock Investors are Growing Curious About Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Duncan Research (NASDAQ:CLRB) www.duncanindependent.com - September 27 at 4:16 PM
	Keen Investors Find News on Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Duncan Research (NASDAQ:CLRB) www.duncanindependent.com - September 24 at 8:30 AM
	Under the Microscope, Zeroing in at Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Duncan Research (NASDAQ:CLRB) www.duncanindependent.com - September 23 at 9:24 AM
	Cellectar Biosciences To Present at OktoberINVESTfest - GlobeNewswire (press release) (NASDAQ:CLRB) globenewswire.com - September 21 at 4:52 PM
	Cellectar Biosciences To Present at OktoberINVESTfest (NASDAQ:CLRB) www.publicnow.com - September 21 at 4:52 PM
	Penny Stock Investors Take an Interest in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Duncan Research (NASDAQ:CLRB) www.duncanindependent.com - September 21 at 8:19 AM
	Cellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference - GlobeNewswire (press release) (NASDAQ:CLRB) globenewswire.com - September 21 at 8:19 AM
	Cellectar Biosciences : to Present at Ladenburg Thalmann 2016 Healthcare Conference (NASDAQ:CLRB) www.4-traders.com - September 20 at 10:05 AM
	Cellectar Biosciences to Present at Ladenburg Thalmann 2016 Healthcare Conference (NASDAQ:CLRB) finance.yahoo.com - September 19 at 9:00 AM
	Cellectar Biosciences Incorporated (NASDAQ:CLRB) Short Interest Decreased By 3.6% - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - September 17 at 8:59 AM
	Stock Turning Lower in Trade: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - September 14 at 4:21 PM
	Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M ... - GlobeNewswire (press release) (NASDAQ:CLRB) globenewswire.com - September 14 at 8:31 AM
	Stock Gapping Higher Pre-Market: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - September 13 at 9:03 AM
	Time To Put On The Watch List? - Cellectar Biosciences, Inc. (NASDAQ:CLRB), Lpath Inc. (NASDAQ:LPTN) - The Voice Registrar (NASDAQ:CLRB) voiceregistrar.com - September 13 at 9:03 AM
	Cellectar Biosciences Inc (NASDAQ:CLRB): Why We're Not Willing To Pull The Trigger Just Yet - Street Register (NASDAQ:CLRB) streetregister.com - September 13 at 9:03 AM
	CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:CLRB) biz.yahoo.com - September 13 at 9:03 AM
	Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant (NASDAQ:CLRB) finance.yahoo.com - September 12 at 9:04 AM
	8:34 am Cellectar Biosciences announces CLR 131 will be evaluated by the University of Wisconsin in combination with external beam radiation as a potential combination treatment for head & neck cancers (NASDAQ:CLRB) finance.yahoo.com - September 12 at 9:04 AM
	Cellectar Biosciences Inc. (CLRB) Has Risen To Nearly A 2-Month High (NASDAQ:CLRB) www.rttnews.com - September 10 at 8:56 AM
	HC Stocks in Top Row= Cellectar Biosciences Inc (CLRB), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release) (NASDAQ:CLRB) sharemarketupdates.com - September 9 at 4:09 PM
	Biotech Stocks Worth a Closer Look: GTx, Inc. (NASDAQ:GTXI), Cellectar Biosciences, Inc. (NASDAQ:CLRB) - The Voice Registrar (NASDAQ:CLRB) voiceregistrar.com - September 9 at 4:09 PM
	Healthcare Stocks To Watch: Cellectar Biosciences, Inc. (NASDAQ:CLRB), BioTime, Inc. (NYSEMKT:BTX) - National Daily Press (NASDAQ:CLRB) www.nationaldailypress.com - September 9 at 9:05 AM
	Shares Higher in Today's Session: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - September 8 at 4:09 PM
	Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference (NASDAQ:CLRB) finance.yahoo.com - September 6 at 9:09 AM
	Shares Gapping Higher Pre-Market: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - September 3 at 8:55 AM
	HC Stocks in Top Row- Cellectar Biosciences Inc (NASDAQ:CLRB), Exelixis, Inc. (NASDAQ:EXEL) - share market updates (press release) (NASDAQ:CLRB) sharemarketupdates.com - September 3 at 8:55 AM
	Stock Down in Trading Session: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - September 1 at 11:48 AM
	Crowd Sentiment & Wall Street Views on Cellectar Biosciences, Inc. (NASDAQ:CLRB)? - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - August 23 at 8:26 AM
	CELLECTAR BIOSCIENCES, INC. Financials (NASDAQ:CLRB) finance.yahoo.com - August 18 at 4:19 PM
	SeeThruEquity Issues Update on Cellectar Biosciences, Inc. (Nasdaq: CLRB) (NASDAQ:CLRB) finance.yahoo.com - August 18 at 11:05 AM
	Cellectar Biosciences Inc (NASDAQ:CLRB) Might Be Due A Bounce - Street Register (NASDAQ:CLRB) streetregister.com - August 17 at 4:25 PM
	Cellectar Biosciences Inc (NASDAQ:CLRB) Might Be Due A Bounce (NASDAQ:CLRB) streetregister.com - August 17 at 11:17 AM
	Edited Transcript of CLRB earnings conference call or presentation 15-Aug-16 12:30pm GMT (NASDAQ:CLRB) finance.yahoo.com - August 17 at 11:17 AM
	Shares Trading Down in Session: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Post News (NASDAQ:CLRB) www.kentuckypostnews.com - August 16 at 9:31 PM
	Cellectar Biosciences announces recent key accomplishments (NASDAQ:CLRB) medicalphysicsweb.org - August 16 at 4:18 PM
	Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results (NASDAQ:CLRB) www.publicnow.com - August 11 at 10:05 PM
	CELLECTAR BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CLRB) biz.yahoo.com - August 11 at 4:24 PM
	Cellectar Biosciences to Host Conference Call on August 15 to Report Second Quarter 2016 Financial Results and Corporate Performance (NASDAQ:CLRB) www.publicnow.com - August 8 at 9:06 AM
	Cellectar Biosciences (CLRB) Receives Multimillion Second Phase of NCI SBIR Contract for CLR 131 Phase 2 (NASDAQ:CLRB) www.streetinsider.com - August 3 at 4:22 PM
	Cellectar Biosciences (CLRB) Receives Multimillion Second Phase of NCI SBIR Contract for CLR 131 Phase 2 - StreetInsider.com (NASDAQ:CLRB) www.streetinsider.com - August 3 at 11:35 AM
	CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant (NASDAQ:CLRB) biz.yahoo.com - July 27 at 4:04 PM
	Cellectar Biosciences, Inc. (NASDAQ:CLRB): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:CLRB) www.engelwooddaily.com - July 22 at 11:46 AM
	StockNewsNow.com : Publishes New SNNLive Video Interview with Cellectar Biosciences, Inc. Discussing Corporate Updates and Clinical Development (NASDAQ:CLRB) www.4-traders.com - July 21 at 9:48 PM
	StockNewsNow.com Publishes New SNNLive Video Interview with Cellectar Biosciences, Inc. Discussing Corporate Updates and Clinical Development (NASDAQ:CLRB) finance.yahoo.com - July 21 at 8:30 AM
	Increased Stock Volatility Watch: Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Engelwood Daily (NASDAQ:CLRB) www.engelwooddaily.com - July 20 at 5:24 PM
	CELLECTAR BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, (NASDAQ:CLRB) biz.yahoo.com - July 20 at 4:03 PM
	Cellectar Biosciences Incorporated (NASDAQ:CLRB) Sellers Covered 3.93% of Their Shorts - Consumer Eagle (NASDAQ:CLRB) www.consumereagle.com - July 20 at 11:46 AM
	Equity Roundup: Stock Performance Focus on Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Press Telegraph (NASDAQ:CLRB) presstelegraph.com - July 20 at 11:46 AM
	Cellectar Biosciences Appoints Jarrod Longcor Senior Vice President of Corporate Development and Operations (NASDAQ:CLRB) finance.yahoo.com - July 20 at 8:30 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Cellectar Biosciences, Inc. (NASDAQ:CLRB) - TGP (NASDAQ:CLRB) telanaganapress.com - July 19 at 4:22 PM